Healthcare giant GlaxoSmithKline plc (GSK) is currently undergoing a global restructuring to separate its consumer healthcare business from its pharmaceutical business into two separate legal entities. The consumer healthcare business will be demerged into newly independent company, Haleon. Renowned brands, including those with a strong presence in Pakistan, including Sensodyne, ENO and Panadol will comprise the portfolio of Haleon.
GSK has multiple subsidiaries in Pakistan, and employs over 1500 persons across departments and functions. With the division and separation of the two businesses, it is imperative for GSK to seamlessly transition its employees between the two companies.
RIAA Barker Gillette (Pakistan) has been engaged to assist GSK with this restructuring, and in particular advise on related employment and labour related matters in Pakistan. Our team led by Partner – Pakistan Shafaq Rehman and Associate Parus Qureshi are advising on this matter.
For more information on the restructuring, please visit https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/
